Patents Assigned to Amygdala Neurosciences, Inc.
-
Publication number: 20230399307Abstract: Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and and compulsive eating disorder, and/or anxiety disorder, each individually or concurrent.Type: ApplicationFiled: July 17, 2023Publication date: December 14, 2023Applicant: Amygdala Neurosciences, Inc.Inventor: Brent BLACKBURN
-
Publication number: 20230399315Abstract: Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and/or anxiety disorder, each individually or concurrent.Type: ApplicationFiled: June 13, 2023Publication date: December 14, 2023Applicant: Amygdala Neurosciences, Inc.Inventor: Brent BLACKBURN
-
Publication number: 20230399299Abstract: Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and/or anxiety disorder, each individually or concurrent.Type: ApplicationFiled: June 13, 2023Publication date: December 14, 2023Applicant: Amygdala Neurosciences, Inc.Inventor: Brent Blackburn
-
Publication number: 20210220376Abstract: Disclosed herein are methods of treating addiction to a dopamine-producing agent (e.g., amphetamine, cocaine, nicotine, opioids) in patient populations that do not exclude alcohol consumption during treatment.Type: ApplicationFiled: April 7, 2021Publication date: July 22, 2021Applicant: Amygdala Neurosciences, Inc.Inventors: Ivan Diamond, Louis G. Lange, Peter M. Strumph
-
Publication number: 20210145844Abstract: Disclosed is a combination therapy for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of an ALDH-2 inhibitor, such as a compound of Formula (I), in combination with an amount of the nicotinic acetylcholine receptor agonist, varenicline. The disclosure further relates to methods and pharmaceutical compositions useful with the combination therapy.Type: ApplicationFiled: January 25, 2021Publication date: May 20, 2021Applicant: Amygdala Neurosciences, Inc.Inventor: Brent BLACKBURN
-
Publication number: 20200237789Abstract: Disclosed is a novel combination therapy to reduce or prevent the acquisition of a conditioned response in a mammal comprising administering to the mammal a therapeutically effective amount of an aldehyde dehydrogenase (ALDH-2) inhibitor compound, such as a compound of Formula (I), in combination with a substance that produces the conditioned response, such as a medication containing a dopamine-producing agent such as an opioid, whereby the combination acts to reduce or prevent the acquisition of a conditioned response, and the deleterious side-effect of misuse, dependence, abuse, and/or addiction.Type: ApplicationFiled: April 15, 2020Publication date: July 30, 2020Applicant: Amygdala Neurosciences, Inc.Inventors: Brent Blackburn, Ivan Diamond, Louis G. Lange, Peter M. Strumph
-
Patent number: 10507215Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.Type: GrantFiled: May 8, 2018Date of Patent: December 17, 2019Assignee: Amygdala Neurosciences, Inc.Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
-
Publication number: 20180338989Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.Type: ApplicationFiled: May 8, 2018Publication date: November 29, 2018Applicant: Amygdala Neurosciences, Inc.Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
-
Patent number: 9987295Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.Type: GrantFiled: March 31, 2017Date of Patent: June 5, 2018Assignee: Amygdala Neurosciences, Inc.Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
-
Publication number: 20170266210Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.Type: ApplicationFiled: March 31, 2017Publication date: September 21, 2017Applicant: Amygdala Neurosciences, Inc.Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G. Strickley, Chandrasekar Venkataramani, Jeff Zablocki